<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03480308</url>
  </required_header>
  <id_info>
    <org_study_id>paravertebral block</org_study_id>
    <nct_id>NCT03480308</nct_id>
  </id_info>
  <brief_title>Effect of Addition of Fentanyl or Dexamethasone or Both to Bupivacaine in Paravertebral Block for Patients Undergoing Major Breast Surgery</brief_title>
  <official_title>Effect of Addition of Fentanyl or Dexamethasone or Both to Bupivacaine in Paravertebral Block for Patients Undergoing Major Breast Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluated the analgesic efficacy of fentanyl and dexamethasone in combination with
      bupivacaine for single-shot paravertebral block (PVB) in patients undergoing major breast
      surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study evaluated the analgesic efficacy of fentanyl and dexamethasone in combination with
      bupivacaine for single-shot paravertebral block (PVB) in patients undergoing major breast
      surgery.

      Patients will receive ultrasound guided paravertebral block and stratified into 3 groups
      according to medication used :

      Group 1 : bupivacaine (0.5%) 20 ml , fentanyl 1 μg/kg Group 2 : bupivacaine (0.5%) 20 ml ,
      dexamethasone 4 mg Group 2 : bupivacaine (0.5%) 20 ml , fentanyl 1 μg/kg , dexamethasone 4 mg
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2018</start_date>
  <completion_date type="Anticipated">May 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients will receive ultrasound guided paravertebral block and stratified into 3 groups according to medication used :
Group 1 : bupivacaine (0.5%) 20 ml , fentanyl 1 μg/kg Group 2 : bupivacaine (0.5%) 20 ml , dexamethasone 4 mg Group 2 : bupivacaine (0.5%) 20 ml , fentanyl 1 μg/kg , dexamethasone 4 mg</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
    <masking_description>Randomization Will be Done Using Computer Generated Tables</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Pain assessment</measure>
    <time_frame>one day postoperative</time_frame>
    <description>Pain assessment by the aid of Visual analogue scale (VAS) Ranging from 0=no pain,
mild pain,
moderate pain,
severe pain and lastly 4 =excruciating pain higher values represent worse outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Increase analgesic requirements postoperatively</measure>
    <time_frame>one day postoperatively</time_frame>
    <description>Any additional analgesia during the 1st 24 hours will be covered by paracetamol 1000 mg IV infusion slowly on 10 minutes according to the patient's request. After 24 hours the total doses will be calculated</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">1</enrollment>
  <condition>Paravertebral Block</condition>
  <arm_group>
    <arm_group_label>Bupivacaine fentanyl group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive bupivacaine (0.5%) 20 ml , fentanyl 1 μg/kg in paravertebral block</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bupivacaine dexamethasone group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive bupivacaine (0.5%) 20 ml , dexamethasone 4 mg in paravertebral block</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bupivacaine fentanyl dexamethasone group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive bupivacaine (0.5%) 20 ml , fentanyl 1 μg/kg , dexamethasone 4 mg in paravertebral block</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fentanyl</intervention_name>
    <description>Patients will receive bupivacaine (0.5%) 20 ml , fentanyl 1 μg/kg in paravertebral block</description>
    <arm_group_label>Bupivacaine fentanyl group</arm_group_label>
    <arm_group_label>Bupivacaine fentanyl dexamethasone group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Patients will receive bupivacaine (0.5%) 20 ml , Dexamethasone 4mg in paravertebral block</description>
    <arm_group_label>Bupivacaine dexamethasone group</arm_group_label>
    <arm_group_label>Bupivacaine fentanyl dexamethasone group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine</intervention_name>
    <description>Bupivacaine</description>
    <arm_group_label>Bupivacaine fentanyl group</arm_group_label>
    <arm_group_label>Bupivacaine dexamethasone group</arm_group_label>
    <arm_group_label>Bupivacaine fentanyl dexamethasone group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: 18-70 years.

          -  Sex: females

          -  ASA physical status: I-II.

          -  Operation: major breast surgery

        Exclusion Criteria:

          -  - Patient refusal.

          -  History of cardiac disease, psychological disorders, respiratory diseases including
             asthma, renal or hepatic failure.

          -  Coagulation disorders.

          -  Infection at the puncture site

          -  Allergy to study medications.

          -  Chronic use of pain medications.

          -  Respiratory tract in¬fection within the last 2 weeks.

          -  Neurological deficit
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Amonios khalil</last_name>
    <phone>01023466456</phone>
    <email>amonios_khalil@yahoo.com</email>
  </overall_contact>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 16, 2018</study_first_submitted>
  <study_first_submitted_qc>March 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2018</study_first_posted>
  <last_update_submitted>March 27, 2018</last_update_submitted>
  <last_update_submitted_qc>March 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Amonios khalil</investigator_full_name>
    <investigator_title>doctor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Fentanyl</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

